

PHARMACY PRE-AUTHORIZATION CRITERIA

DRUG (S)	Mepron (atovaquone)
Policy#	13120
Indications	 Mepron is indicated for the prevention of <i>Pneumocystis carinii</i> pneumonia in patients who are intolerant to trimethoprim-sulfamethoxazole (TMP-SMX) Mepron is indicated for the acute oral treatment of mild-to-moderate PCP in patients who are intolerant to TMP-SMX.
CRITERIA	ConnectiCare will consider Mepron to be medically necessary in patients who meet at least one of the following criteria: • Patient requires prophylaxis treatment or treatment for an acute <i>Pneumocystis carinii</i> pneumonia infection AND • Patient has an intolerance to, or treatment failure, or contraindication to trimethoprimsulfamethoxazole (TMP-SMX). A physician chart note is required documenting the trial and outcome (if the claims can not be seen in the patient's prescription history). OR • Patient is being treated for active Babesiosis (Babesia) infection. (not FDA-approved, but sufficient evidence to support its use) AND • Laboratory confirmation of babesiosis is required
LIMITATIONS	For the treatment of Babesiosis, approval will be limited to 10 days.
REFERENCES	 Mepron full prescribing information.GlaxoSmithKline Research Triangle Park, NC The Sanford Guide To Antimicrobial Therapy 2004. 34th Edition.
P&T REVIEW HISTORY	3/05, 6/07, 6/08, 9/09, 9/10, 12/11, 10/12, 10/13, 10/14, 11/15, 8/16, 8/17, 7/18
REVISION RECORD	